BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $116
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout maintains a Market Perform rating on Novartis (NVS) and raises the price target from $114 to $116.
April 24, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital maintains a Market Perform rating on Novartis and raises the price target from $114 to $116.
The increase in price target by BMO Capital suggests a positive outlook on Novartis's future performance. This adjustment reflects an analyst's confidence in the company's ability to achieve or surpass the new target, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100